S-108 is a targeted cytotoxic peptide conjugate which is a hybrid
molecule composed of a synthetic peptide carrier and a well-known cytotoxic
agent, doxorubicin. The design of this product allows for the specific
binding and selective uptake of the cytotoxic conjugate by
LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells
that express these receptors results in its accumulation in the malignant
tissue. This binding is followed by internalization and retention of the
cytotoxic drug, doxorubicin, in the cells. Therefore, since they target
specific cells, cytotoxic conjugates are postulated to be less toxic, have
less side-effects and are more effective in vivo than the respective
non-conjugated/non-linked cytotoxic agents in inhibiting tumor growth.
About ovarian and endometrial cancer
Ovarian cancer is one of the most common gynaecologic malignancies and
the fifth most frequent cause of cancer death in women, with most of the
cases occurring in women between 50 and 75 years of age. Overall, ovarian
cancer accounts for 4% of all cancer diagnosis in women and 5% of all
cancer deaths. Approximately 26,000 new cases and 17,000 deaths from this
disease are estimated in the European community every year.
(Source: Gynecologic Oncology, Volume 92, Issue 3, March 2004, Pages
Cancer of the endometrium is the most common gynaecologic malignancy
and accounts for 6% of all cancers in women. The majority of the cases
occur in postmenopausal women, with the largest number of women developing
their cancers during the sixth decade. Approximately 38,000 new cases and
9,000 deaths from this disease are estimated annually in Europe.
(Source: Annals of Oncology 15:1149-1150, 2004)
About AEterna Zentaris Inc.
AEterna Zentaris Inc. is a global biopharmaceutical company focused on
endocrine therapy and oncology with proven expertise in drug discovery,
development and commercialization.
News releases anPage: 1 2 3 4 Related biology technology :1
. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment2
. AEterna Zentaris Announces Outcome of Managements Strategic Review3
. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York4
. AEterna Zentaris completes management team with the appointment of Chief Medical Officer5
. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year6
. Immtech Reports Fiscal Third Quarter 2008 Results7
. Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out8
. Cryo-Cell International, Inc. Reports Results for Fiscal 20079
. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 200710
. Bunge Reports Fourth Quarter Net Income of $245 Million11
. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months